Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.62 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.62 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.55 |
| ▸ | PPARG | P37231 | 7/20 | 0.55 |
| ▸ | PPARD | Q03181 | 7/20 | 0.55 |
| ▸ | PPARA | Q07869 | 7/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.55 |
| ▸ | TSHR | P16473 | 4/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | TLR2 | O60603 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | FABP4 | P15090 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.55 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | PDE4A | P27815 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Decanoic Acid SCHEMBL4271763 | 1.00 | FFAR4 (0.62) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL1553302 | 0.86 | SPHK1 (0.59) | FFAR1GPR84MAPT | |
| SCHEMBL1275084 | 0.84 | FFAR4 (0.78) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL10952918 | 0.84 | FFAR4 (0.78) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL6300670 | 0.84 | FFAR4 (0.78) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL8539791 | 0.84 | FFAR4 (0.78) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL17911294 | 0.84 | FFAR4 (0.78) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL4402579 | 0.84 | FFAR4 (0.78) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL8633366 | 0.84 | FFAR4 (0.78) | FFAR4FFAR1GPR84PPARGPPARD | |
| SCHEMBL3758559 | 0.84 | FFAR4 (0.78) | FFAR4FFAR1GPR84PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682068-B2 | Transdermal therapeutic system for extended dosing of pramipexole in treating neurological disorders | MYLAN INC. (US) | 2017-06-20 | — | — | US | claimed |
| US-20160113908-A1 | Transdermal Therapeutic System for Extended Dosing of Pramipexole in Treating Neurological Disorders | MYLAN INC. | 2016-04-28 | — | — | US | claimed |
| EP-2999444-A2 | TRANSDERMAL EXTENDED DOSING OF PRAMIPEXOLE FOR NEUROLOGICAL DISORDERS | Mylan Inc. (US) | 2016-03-30 | — | — | EP | claimed |
| US-20090175928-A1 | Lip Plaster | LABTEC GESELLSCHAFT FUR TECHNOLOGISCHE FORSCHUNG UND ENTWICKLUNG MBH (DE) | 2009-07-09 | — | — | US | claimed |
| US-20080279915-A1 | Matrix-Controlled Transdermal Therapeutic System Based on an Adhesive for Administering Norelgestromin or the Combination Thereof with an Estrogen | HEXAL AG (DE) | 2008-11-13 | — | — | US | claimed |
| US-9682068-B2 | Transdermal therapeutic system for extended dosing of pramipexole in treating neurological disorders | MYLAN INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160113908-A1 | Transdermal Therapeutic System for Extended Dosing of Pramipexole in Treating Neurological Disorders | MYLAN INC. | 2016-04-28 | — | — | US | disclosed |
| EP-2999444-A2 | TRANSDERMAL EXTENDED DOSING OF PRAMIPEXOLE FOR NEUROLOGICAL DISORDERS | Mylan Inc. (US) | 2016-03-30 | — | — | EP | disclosed |
| US-20090175928-A1 | Lip Plaster | LABTEC GESELLSCHAFT FUR TECHNOLOGISCHE FORSCHUNG UND ENTWICKLUNG MBH (DE) | 2009-07-09 | — | — | US | disclosed |
| US-20080279915-A1 | Matrix-Controlled Transdermal Therapeutic System Based on an Adhesive for Administering Norelgestromin or the Combination Thereof with an Estrogen | HEXAL AG (DE) | 2008-11-13 | — | — | US | disclosed |
| US-7344733-B2 | Matrix controlled transdermal therapeutic system for the use of pramipexole and ropinirole | HEXAL AG (DE) | 2008-03-18 | — | — | US | disclosed |
| US-20070166364-A1 | Transdermal Therapeutic System | BEIER CORNELIA | 2007-07-19 | — | — | US | disclosed |
| US-7220473-B2 | Storage stability | HEXAL AG (DE) | 2007-05-22 | — | — | US | disclosed |
| US-20040253299-A1 | Transdermal therapeutic system (reservoir-tts) for using pramipexole and ropinirole | HEXAL AG (DE) | 2004-12-16 | — | — | US | disclosed |
| US-20040052835-A1 | Matrix controlled transdermal system for stabile derivatives of ace inhibitors | HEXAL AG (DE) | 2004-03-18 | — | — | US | disclosed |
| US-20040047901-A1 | Storage stability | HEXAL AG (DE) | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160113908-A1 | Transdermal Therapeutic System for Extended Dosing of Pramipexole in Treating Neurological Disorders | ACHE, TES, ADAMTS5 | FFAR4 2953/4885FFAR1 3899/4885GPR84 1955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.